Attempts to improve locoregional chemotherapy for the prevention of colonic cancer liver metastasis in the rat

Gastroenterologie Clinique et Biologique

Volumn 30, Issue 8-9, 2006, Pages 1019-1025

  Benoit, Laurent ^a,c   Favoulet P, Patrick ^a   Ortega Deballon, Pablo ^a   Cheynel, Nicolas ^a   Anusca, Anisoara ^a   Bamourou, Diane ^a   Bonnetain, Franck ^a   Rat, Patrick ^a   Favre, Jean Pierre ^a   Chauffert, Bruno ^a,b  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b CENTRE GEORGES FRANÇOIS LECLERC   (France)

^c HÔPITAL DU BOCAGE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUORO URACILE; FLUOROURACIL; GEMCITABINE; MELPHALAN; MITOMYCIN C; PIRARUBICIN; TETRAZOLIUM; THEPRUBICINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL STRAIN HT29; CLAMP; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; FLUORESCENCE MICROSCOPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIVER METASTASIS; LIVER TOXICITY; LIVER VEIN; MALE; NONHUMAN; PORTAL VEIN; RAT; STATISTICAL SIGNIFICANCE; TUMOR CELL LINE;

EID: 33750744469     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(06)73377-2     Document Type: Article

References (32)

1. Greenway B. Hepatic metastases from colorectal cancer: resection or not. Br J Surg 1988;75:513-9.
2. Steele G Jr, Ravikumar TS. Resection of hepatic metastases from colorectal cancer: biologic perspectives. Ann Surg 1989;210:127-38.
3. Buyse M, Zeleniuch Jacquotte A, Chalmers TC. Adjuvant therapy of colorectal cancer. Why we still don't know. JAMA 1988;259:3571-8.
4. Zalcberg JR, Siderov J, Simes J. The role of 5-fluorouracil dose in the adjuvant therapy of colorectal cancer. Ann Oncol 1996;7:41-6.
5. Ross P, Norman A, Cunningham D, Webb A, Iveson T, Padhani A, et al. A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 1997;8:995-1001.
6. Cassidi J. Thymidilate synthase inhibitors in colorectal cancer. Semin Oncol 2000;26:83-7.
7. Kaye SB. New antimetabolites in cancer chemotherapy and their clinical impact. Br J Cancer 1998;7:1-7.
8. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Wiliamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
9. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.
10. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-12.
11. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre pooled analysis of B2 colon cancer trials (IMPACT B2). J Clin Oncol 1999;17:1356-63.
12. Rougier P, Ducreux M, Seitz JF. Place de la chimiothérapie dans la stratégie thérapeutique des cancers digestifs. Ed. John Libbey: Paris Eurotext 2001.
13. Archer S, Gray B. Intraperitoneal 5-fluorouracil infusion for treatment of both peritoneal and liver micrometastases. Surgery 1990;108:502-7.
14. Kemeny N, Fata F. Arterial, portal, or systemic chemotherapy for patients with hepatic metastasis of colorectal carcinoma. J Hepatobiliary Pancreat Surg 1999;6:39-49.
15. Martin MS, Martin F, Michel MF, Hammann A. Growth characteristics and metastatic potential of seven intestinal carcinoma lines serially passaged in syngenic rats. Virchows Arch A Pathol Anat Histopathol 1991;418:193-9.
16. Munck JN, Rougier P, Chabot GG, Ramirez LH, Bognel C, Lumbroso J, et al. Phase I and pharmacological study of intra-arterial hepatic administration of pirarubicine in patients with advanced hepatic metastases. Eur J Cancer 1994;30:289-94.
17. Pelletier H, Millot JM, Chauffert B, Manfait M, Genne P, Martin F. Mechanisms of resistance of confluent human and rat colon cancer cells to anthracyclines: alteration of drug passive diffusion. Cancer Res 1990;50:6626-31.
18. Chauffert B, Dimanche-Boitrel MT, Genne P, Petit JM, Onier N, Jeannin JF. Experimental chemotherapy of peritoneal carcinomatosis of colonic origin in rats. Gastroenterol Clin Biol 1992;16:215-9.
19. Steib A, Schmidt-Mutter C, Bachelier P, Dupeyron JP. Anesthésie pour chirurgie hépatique. Conférence d'utilisation. Edition scientifique et Médicale Elsevier SAS et Sfar 2001:369-384.
20. Dimanche-Boitrel MT, Pelletier H, Genne P, Petit JM, Le Grimellec C, Canal P, et al. Confluence-dependent resistance in human colon cancer cells: role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells. Int J Cancer. 1992;50:677-82.
21. Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Meyers CE, Young RC. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res 1979;39:3209-14.
22. Favoulet P, Cercueil JP, Faure P, Osmak L, Isambert N, Beltramo JL, et al. Increased cytotoxicity and stability of Lipiodol-pirarubicine emulsion compared to classical doxorubicin-Lipiodol: potential advantage for chemoembolization of unresectable hepatocellular carcinoma. Anticancer Drugs. 2001;12:801-6.
23. Chauffert B, Martin MS, Hamman A, Michel MF, Martin F. Amiodarone-induced enhancement of doxorubicin and 4′-deoxydoxorubicin cytotoxicity to rat colon cancer cells in vitro and in vivo. Cancer Res 1986;46:14-8.
24. Pelletier H, Millot JM, Chauffert B, Manfait M, Genne P, Martin P. Mechanisms of resistance of confluent human and rat colon cancer cells to anthracyclines:alteration of drug passive diffusion. Cancer Res 1990;50:6626-31.
25. Favoulet P, Benoit L, Osmak L, Polycarpe E, Esquis P, Duvillard C, et al. Prevention of peritoneal carcinomatosis from colon cancer cell seeding using a pirarubicine solution in rats and nude Mice. World J Surg 2004;28:451-6.
26. Benhamou JP, Bircher J, McIntyre N, Rizello M, Rodes J. Hépatologie Clinique. Histologie du foie et des voies biliaires p: 12-20. Médecine-Sciences. Flammarion, Paris 1993. pp : 12-20.
27. Taylor I, Machin D, Mullee M, Trotter G, Cooke T, West C. A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. Br J Surg 1985;72:359-63.
28. Rougier P, Sahmoud T, Nitti D, Curran D, Doci R, De Waele B, et al. Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. Lancet 1998 12;352:910.
29. Kemeny , Garay CA, Gurtler J, Hocherster H, Kennedy P, Benson A, et al. Randomized multicenter phase II trial of bolus plus infusional of fluorouracil/leucovorin compared with fluorouracil/leucovorine plus oxaliplatin as third-line treatment with advanced colorectal cancer. J Clin Oncol 2004;22:4753-61.
30. Plasencia C, Abad A, Martinez-Balibrea E, Taron M. Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human cancer cell line. Ivest New Drugs 2004;22:399-409.
31. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, Fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51.
32. Macdonald JS. Clinical overview: adjuvant therapy of gastrointestinal cancer. Cancer Chemother Pharmacol 2004:54(Suppl 1):S4-11.